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We previously reported that Pseudomonas aeruginosa PA14 secretes a protein that can reduce the apical
membrane expression of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Here we
report that we have used a proteomic approach to identify this secreted protein as PA2394, and we have named
the gene cif, for CFTR inhibitory factor. We demonstrate that Cif is a secreted protein and is found associated
with outer membrane-derived vesicles. Expression of Cif in Escherichia coli and purification of the C-terminal
six-His-tagged Cif protein showed that Cif is necessary and sufficient to mediate the reduction in apical
membrane expression of CFTR and a concomitant reduction in CFTR-mediated Cl ion secretion. Cif
demonstrates epoxide hydrolase activity in vitro and requires a highly conserved histidine residue identified in
/ hydrolase family enzymes to catalyze this reaction. Mutating this histidine residue also abolishes the
ability of Cif to reduce apical membrane CFTR expression. Finally, we demonstrate that the cif gene is
expressed in the cystic fibrosis (CF) lung and that nonmucoid isolates of P. aeruginosa show greater expression
of the gene than do mucoid isolates. We propose a model in which the Cif-mediated decrease in apical
membrane expression of CFTR by environmental isolates of P. aeruginosa facilitates the colonization of the CF
lung by this microbe.
The bacterium Pseudomonas aeruginosa, a known pathogen
of a variety of organisms, has the ability to infect individuals
who are immunocompromised due to injury or disease (19, 34,
52). Of prime interest to those studying P. aeruginosa is its role
in the human genetic disease cystic fibrosis (CF). Up to 90% of
individuals suffering from CF become infected with P. aerugi-
nosa during their lifetime, and this organism is the leading
cause of morbidity and mortality among CF patients (5, 17). In
the majority of cases, colonization of the CF airway by P.
aeruginosa leads to a chronic infection that is refractory to
antimicrobial therapy (8, 22).
The disease CF is the result of mutations within the cystic
fibrosis transmembrane conductance regulator (CFTR), the
most common of which is a deletion of the phenylalanine at
residue 508 (F508) (18, 41, 42, 50). CFTR localizes to the
apical membrane of epithelial tissues, where it directly regu-
lates the flux of chloride ions across the apical membrane and
indirectly regulates the flux of sodium ions and water (25, 41).
The F508 mutation results in mislocalization of CFTR from
the apical membrane and thus alters the flux of ions and water
across this membrane. Individuals homozygous for this allele
demonstrate altered sodium and chloride secretion, leading to
an increase in mucus and air-surface liquid viscosity and a
general decrease in air-surface liquid height. This increased
viscosity as well as the ensuing ciliastasis allow for the coloni-
zation of the lung by a variety of microbes (5). These initial
infections eventually cede to P. aeruginosa, which establishes
the aforementioned chronic infection.
The ability of P. aeruginosa to colonize the CF airway and
rapidly become the dominant organism has been studied thor-
oughly and yet is still poorly understood. It is likely that the
infection process is multifactorial. For example, the secretion
of well-characterized virulence factors, such as elastase and
pyocyanin, results in tissue damage and eradication of other
microbes (6, 27, 29, 53), perhaps allowing P. aeruginosa to
dominate the CF airway. Alternatively, it has been proposed
that P. aeruginosa directly interacts with CFTR (39). A recent
model proposes that P. aeruginosa initially colonizes the lung
as a free-swimming bacterium but quickly begins to form com-
plex communities embedded in an exopolymeric matrix, known
as biofilms, which demonstrate significantly more resistance to
antimicrobial chemotherapy than do their planktonic counter-
parts (16, 21, 46).
We have evidence that P. aeruginosa may exacerbate the
problems associated with decreased CFTR function. Previous
work by our group demonstrated that P. aeruginosa secretes a
factor capable of reducing apical membrane expression of both
wild-type (WT) CFTR and F508-CFTR, termed Cif (CFTR
inhibitory factor) (48). We present here the purification, iden-
tification, and characterization of Cif, a protein encoded by the
PA2934 locus of P. aeruginosa PA14.
MATERIALS AND METHODS
Bacterial strains, media, and chemicals. All of the bacterial strains and plas-
mids used in this study are shown in Table 1. All bacterial strains were grown in
lysogeny broth (LB) (3) unless otherwise noted. The growth medium was sup-
plemented with antibiotics at the following concentrations: gentamicin, 10 g/ml
(Escherichia coli) or 100 g/ml (P. aeruginosa); and ampicillin, 150 g/ml (E. coli)
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TABLE 1. Strains, plasmids, and primers used for this study
Strain, plasmid, or primer Relevant genotype, description, or sequence (5–3) Source or reference
Strains
P. aeruginosa strains
PA14 Wild type 40
SMC3498 PA14 PA2934 single-crossover mutant This study
SMC3499 PA14 PA4476 single-crossover mutant This study
SMC3500 PA14 PA1914 single-crossover mutant This study
SMC3501 PA14 plus pMQ70 This study
SMC3502 PA14 PA2934 This study
SMC3503 SMC3502 plus pDPM73 (PA2934-His) This study
SMC3504 SMC3502 plus pMQ70 This study
SMC3505 E. coli Top10 plus pDPM73 (PA2934-His) This study
SMC3506 SMC3498 plus pDPM73 (PA2934-His) This study
SMC3507 E. coli Top10 plus pDPM77 (PA2934-His,H269A) This study
SMC3510 E. coli S17 plus pDPM74 This study
SMC1584 Clinical isolate, nonmucoid This study
SMC1585 Clinical isolate, mucoid This study
SMC1586 Clinical isolate, nonmucoid This study
SMC1587 Clinical isolate, mucoid This study
SMC1588 Clinical isolate, nonmucoid This study
SMC1589 Clinical isolate, mucoid This study
SMC1590 Clinical isolate, mucoid This study
SMC1591 Clinical isolate, nonmucoid This study
SMC1593 Clinical isolate, nonmucoid This study
SMC1596 Clinical isolate, mucoid This study
E. coli strain
Top10 F mcrA (mrr-hsdRMS-mcrBC) f80lacZM15 lacX74 recA1 ara139 (araleu)7697
galU galK rpsL (Strr) endA1 nupG
Invitrogen
Plasmids
pDPM60 PA2934 fragment in pMQ89; Gmr This study
pDPM61 PA4476 fragment in pMQ89; Gmr This study
pDPM66 PA1914 fragment in pMQ89; Gmr This study
pDPM70 WT PA2934 in pMQ71; Cbr Apr This study
pDPM73 PA2934 histidine fusion in pMQ70; Cbr Apr This study
pDPM77 Derivative of pDPM73 carrying H269A mutation This study
pMQ89 Single-crossover mutation vector; Gmr 45
pMQ30 P. aeruginosa suicide vector for clean deletions; Gmr 45
pMQ89 Single-crossover mutation vector; Gmr 45
pMQ70 Arabinose-inducible expression vector; Cbr Apr URA3 45
Primers
PA2934_SXO_for GAGGAATTCCCCGTCCCGAATGGCTTCG
PA2934_SXO_rev CCGCGGATCCGCCAGACCAGCGACTCGCCCTGGGCG
PA4476_SXO_for CCGCGGATCCGTCCTGGGTCTGTGCGCCCTGGTACTGG
PA4476_SXO_rev CCGCGAATTCCGCGCCGACCGCGCTGAGCGACAGCG
PA1914_SXO_for CGCCGGATCCGGCCTGGCGCTGACACCCGCGGCCC
PA1914_SXO_rev CCGCGAATTCGCACTGCCGCGAATGGTCGCCGCGG
PA2934_KO_1 GGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGCCCGCAAGCGG
CTGTTCGTCGCCTGCC
PA2934_KO_2 CTGATCGCCCGGACCGGGACGACGGTTGTGCTTCCTTGGTGGGGTC
PA2934_KO_3 GACCCCACCAAGGAAGCACAACCGTCGTCCCGGTCCGGGCGATCAG
PA2934_KO_4 GTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCCGAACAGCGCG
GTGTCCTTGAAGC
PA2934_comp_for CCGCGCTAGCCCAAGGAAGCACAACCATGATCC
PA2934_comp_rev CCGCGGTACCTCAGCGACCGCGGCTGAGGAAG
PDPM70-His GTATCAGGCTGAAAATCTTCTCTCATCCGCCTCAATGATGATGATGATGATG
GCGACCGCGGCTGAGGAAGTCGATCACCAGG
PA2934_mut_out_for GATTTAATCTGTATCAGGCTGAAAATCTTCTCTCATCCGCCTCAATGATGATG
ATGATGATGGCG
H269A_rev CCATGACCCTCGCCGGCGGCGGCGCCGGCGGCATGGGCACGTTCCAGCTGG
H269A_for CCAGCTGGAACGTGCCCATGCCGCCGGCGCCGCCGCCGGCGAGGGTCATGG
PA2934_mut_out_rev CCATGACCCTCGCCGGCGGCGGCGCCGGCGGCATGGGCACGTTCCAGCTGG
PA2934_rt_1 CTCCTGGCCGGCATCGCCCTGACCTTCTCC
PA2934_rt_2 CCATTCGTACCAGGTCTGGCCGAAGCCGTGC
RplU_rt_1 GGTGGCAAGCAGCACAAAGTCACCG
RplU_rt_2 GCGGACCTTGTCGTGACGGCCGTGG
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or 1.5 mg/ml (P. aeruginosa). All strains were grown at 37°C. Yeast cultures were
grown in either rich (yeast extract-peptone-dextrose) or minimal (SDUra;
Sunrise Science Products, San Diego, CA) medium at 30°C. All restriction
enzymes were purchased from New England Biolabs (Beverly, MA). All plasmids
were constructed in E. coli Top10, using standard protocols, or Saccharomyces
cerevisiae InvSc (Invitrogen, Carlsbad, CA), using in vivo recombination, and
electroporated or conjugated into P. aeruginosa strain PA14 as reported previ-
ously (10, 45).
Purification of Cif. Five-milliliter cultures of P. aeruginosa PA14 were grown
overnight at 37°C, followed by 1:1,000 dilution into 100 ml LB. Cultures were
grown with shaking at 37°C for 18 h. Supernatants were harvested by centrifu-
gation at 7,000  g for 15 min followed by filtration through a 0.22-m filter.
Sterile supernatants were concentrated 10-fold using Amicon Centriprep cen-
trifugation filters per the manufacturer’s instructions (Millipore, Billerica, MA).
Concentrated supernatants were dialyzed against 4 liters of 25 mM morpho-
lineethanesulfonic acid buffer, pH 6.5, for 2 h, using Pierce Slide-a-lyzers with a
10-kDa cutoff (Pierce, Rockford, IL). Samples were then fractionated utilizing a
1-ml Amersham Biosciences HiTrap Q FF anion-exchange chromatography col-
umn (Amersham Biosciences, Uppsala, Sweden), using a stepwise gradient of 0
and 50 mM and 2 M NaCl. Collected fractions were then dialyzed against 4 liters
of phosphate-buffered saline and utilized in the apical CFTR membrane expres-
sion assays described below.
MudPIT analysis of active fractions. Samples for multidimensional protein
identification technology (MudPIT) analysis were lyophilized using a Savant
SC110 Speed-Vac and stored on ice. Samples were submitted to the Keck
Proteomics and Mass Spectrometry facility at Yale University for MudPIT anal-
ysis. The resulting data were analyzed utilizing Mascot and Seaquest software,
and ion masses were compared to those in the available P. aeruginosa PA14
protein database (NCBI accession no. nr 20040730). MudPIT separates proteins
using columns consisting of strong cation-exchange resin in series with reverse-
phase resin. Through cycles of increasing salt and hydrophobicity, peptides are
eluted from the tandem column, resulting in high resolution of the peptides. The
mass spectrometer isolates peptides as they elute and subjects them to collision-
induced dissociation, recording the fragment ions in a tandem mass spectrum.
These spectra are matched to the aforementioned database peptide sequences by
using the SEQUEST algorithm.
Cell lines and cell culture. Madin-Darby canine kidney (MDCK) cells stably
expressing a green fluorescent protein–WT CFTR fusion protein (WT-MDCK
cells) were established and maintained in culture in a 5% CO2-95% air incubator
at 37°C as described previously (37, 38). The addition of green fluorescent
protein to the N terminus of CFTR had no effect on CFTR localization, traf-
ficking, function as a Cl channel, or degradation (37). WT-MDCK cells were
seeded onto Transwell permeable supports (0.2  106 cells on 24-mm-diameter
supports with a 0.4-m pore size) and grown in culture at 33°C for 7 days as
polarized monolayers. Sodium butyrate (5 mM; Sigma-Aldrich) was added to the
WT-MDCK cell culture medium 16 to 18 h before experiments to stimulate
CFTR expression.
Parental human bronchial epithelial CFBE41o cells (F508/F508), origi-
nally immortalized and characterized by Gruenert and colleagues (7, 11), were
stably transduced with WT CFTR (WT-CFBE cells; a generous gift from J. P.
Clancy, Department of Pediatrics, University of Alabama at Birmingham, Bir-
mingham) (2). WT-CFBE cells were cultured in a 5% CO2-95% air incubator at
37°C as previously described (48). To establish polarized monolayers, 1  106
CFBE41o cells were seeded onto 12-mm Snapwell or 24-mm Transwell per-
meable supports (0.4-m pore size; Corning) and grown in air-liquid interface
culture at 37°C for 7 to 9 days.
Determination of CFTR expression in the apical plasma membrane. To iden-
tify active fractions during Cif purification, as well as to assay the Cif activity of
various strains and the purified protein, we used a previously described surface
biotinylation assay (48). Unless otherwise noted, 50 g of purified PA2934-His
was used in all surface biotinylation experiments.
Ussing chamber measurements. Monolayers grown on 12-mm-diameter Snap-
well permeable supports as described above were mounted in an Ussing-type
chamber (Physiological Instruments, San Diego, CA) and bathed in solutions
that were maintained at 37°C and pH 7.4 and stirred using bubbling with 5%
CO2-95% air. The apical bath solution contained 5 mM NaCl, 115 mM sodium
gluconate, 25 mM NaHCO3, 3.3 mM KH2PO4, 0.8 mM K2HPO4, 1.0 mM MgCl2,
1.0 mM CaCl2, and 10 mM mannitol. The basolateral bath solution contained
120 mM NaCl, 25 mM NaHCO3, 3.3 mM KH2PO4, 0.8 mM K2HPO4, 1.0 mM
MgCl2, 1.0 mM CaCl2, and 10 mM glucose. Short-circuit current (Isc) was
measured by clamping the transepithelial voltage across the monolayers to 0 mV
by using a voltage clamp (model VCC MC6; Physiological Instruments) as
described previously (20, 31, 48). Current output from the clamp was digitized
using an analog-to-digital converter (iWorx, Dover, NH). Data collection and
analysis were performed using LabScribe, version 1.8, software (iWorx).
To determine the effects of purified, recombinant PA2934 on the CFTR-
mediated Cl current (Isc), forskolin (20 M) was added to the apical and
basolateral solutions to stimulate Isc, and then 50 g of purified PA2934-His in
buffer or buffer alone (20 mM HEPES buffer, pH 7.5, containing 500 mM NaCl)
was added to the apical bath solution. An equal volume of buffer was also added
to the basolateral side to maintain the apical-to-basolateral Cl concentration
gradient. CFTRinh-172 (5 M), a known inhibitor of CFTR activity (32), was
added to the apical solution as a positive control for inhibition of CFTR Cl
channels. Isc data are expressed as changes in forskolin-stimulated Isc.
Molecular techniques. All molecular techniques were performed as previously
described (47). Single-crossover mutations of the PA1914, PA2934, and PA4476
loci were performed utilizing suicide plasmids based on pMQ89 (45). The dele-
tion of the PA2934 gene was done using previously described methods (30).
Plasmids were propagated in E. coli S17 and conjugated into P. aeruginosa strain
PA14 as previously described (9). Recombinant strains were selected for and
maintained in medium supplemented with gentamicin.
Plasmid construction. Plasmids pDPM60, pDPM61, and pDPM66 contain
400-bp internal regions of the PA2934, PA4476, and PA1914 genes, respec-
tively. The following primers were used to amplify the internal regions of the
PA2934, PA4476, and PA1914 genes: PA2934_SXO_for, PA2934_SXO_rev,
PA4476_SXO_for, PA4476_SXO_rev, PA1914_SXO_for, and PA1914_SXO_rev.
Primers were engineered to create an amplicon that could be digested with EcoRI
and HindIII and ligated into the suicide vector pMQ89 digested in a similar manner.
Construction of the PA2934 deletion plasmid was performed as previously
described (30), using primers PA2934_KO_1, PA2934_KO_2, PA2934_KO_3,
and PA2934_KO_4. Amplicons were created using primer pairs KO_1-KO_2 and
KO_3-KO_4 and were recombined using S. cerevisiae InvSc1 (Invitrogen) into
plasmid pMQ30 linearized with restriction enzymes EcoRI, HindIII, and
BamHI.
Plasmid pDPM70, containing the full-length WT PA2934 open reading frame,
was constructed by amplifying the PA2934 gene with primers PA2934_comp_for
and PA2934_comp_rev, followed by digestion with EcoRI and NheI. The di-
gested amplicon was ligated into pMQ70 (45), which was previously digested in
a similar manner. pDPM73 was created utilizing in vivo recombination cloning as
previously described (45), using pDPM70 digested with NheI and the primer
PDPM70-His, resulting in an in-frame, C-terminal hexahistidine tag fusion to the
PA2934 protein. Plasmid pDPM77, which expresses the PA2934-His protein with
an H269A mutation, was constructed using a similar technique. The PA2934
open reading frame was amplified from pDPM73, using primer pairs
PA2934_mut_out_for-H269A_rev and H269A_for-PA2934_mut_out_rev. The
resulting amplicons were utilized in the in vivo recombination cloning technique,
utilizing linearized pMQ70 as the plasmid backbone.
Purification of PA2934-His protein. E. coli Top10 strain SMC3505, expressing
a C-terminal hexahistidine variant of PA2934 (PA2934-His) from plasmid
pDPM73, was grown overnight at 37°C under selection. Cultures were diluted
1:100 in 4 liters of LB medium supplemented with ampicillin and 0.2% arabinose
and grown for 8 h at 37°C with shaking. Following growth, culture supernatants
were harvested by centrifugation of bacteria at 7,000  g for 20 min. Superna-
tants were filtered through a 0.22-m filter to remove any bacteria remaining in
suspension. Sterile supernatant was then fractionated utilizing an Amersham
HisTrap FF 5 ml nickel-affinity column. Protein was eluted over a 20 to 500 mM
imidazole gradient, with the bulk of the purified PA2934-His protein eluting at
100 mM. Fractions containing the protein were concentrated using an Amicon
Ultra 15 centrifugation filter with a cutoff of 30 kDa per the manufacturer’s
instructions, followed by dialysis against 20 mM HEPES buffer, pH 7.5, contain-
ing 500 mM NaCl. The protein concentration was determined utilizing a Bio-Rad
protein assay kit (Hercules, CA). Purity was determined by resolving the sample
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
detecting it by Coomassie blue staining.
Epoxide hydrolase activity assay. Purified PA2934-His was assayed for the
ability to degrade the epoxide hydrolase synthetic substrate (2S,3S)-trans-3-phe-
nyl-2-oxiranylmethyl 4-nitrophenyl carbonate [(S)-NEPC; Sigma, St. Louis, MO].
PA2934-His was incubated in 20 mM Tris, pH 8.4, 500 mM NaCl with 100 M
(S)-NEPC in a final volume of 200 l at 37°C for 60 min. Degradation of
(S)-NEPC was measured as an increase in absorbance (optical density at 405 nm
[OD405]), utilizing a Molecular Devices SpectraMax M2 plate reader. Reactions
were normalized to controls lacking enzyme, accounting for spontaneous hydro-
lysis of the substrate.
RNA purification from bacterial cells and cDNA synthesis. Strains for quan-
titative real-time reverse transcription-PCR (qRT-PCR) were grown overnight in
LB medium and subsequently diluted 1:100 in LB medium and grown to an
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OD600 of 2.5. Five-hundred-microliter aliquots of cultures were harvested and
centrifuged at 16,000  g for 2 minutes, and the cell pellets were frozen at
80°C. Strains were grown in triplicate, and two samples were harvested per
replicate. RNAs were isolated using a QIAGEN RNeasy kit per the manufac-
turer’s instructions. Following initial purification, samples were incubated with
RNase-free DNase for 1 h at 37°C to further remove contaminating DNA and
were repurified using a QIAGEN RNeasy kit. DNA contamination was assessed
by using samples in a standard PCR assay. The RNA concentration was deter-
mined using a Nanodrop ND-1000 spectrophotometer (Wilmington, DE).
cDNAs were amplified utilizing a Superscript III first-strand polymerase kit
(Invitrogen, Carlsbad, CA) per the manufacturer’s instructions, utilizing random
hexamers to prime the reactions. One microgram of RNA was used for cDNA
synthesis.
RNA purification from sputum and cDNA synthesis. Respiratory sputa were
collected from two individuals with CF and divided such that one sample was
subjected to clinical microbiological analysis while the other was used for the
purposes of RNA isolation. Both sputum samples contained P. aeruginosa, based
on microbiological culture analysis in the DHMC clinical laboratory. After col-
lection, an equal volume of RNALater, an RNA stabilizing agent, was added to
each sample prior to storage at 80°C. To isolate total sputum RNA, samples
were thawed on ice and centrifuged for 10 min at 13,000 rpm. The pellet was
resuspended, followed by homogenization by passage through a 24-gauge syringe
needle several times. Subsequent RNA purification steps were performed with a
QIAGEN RNeasy kit according to the manufacturer’s protocols. Contaminating
DNA was removed using an Ambion DnaseFree kit according to the manufac-
turer’s instructions. RNAs were analyzed spectrophotometrically to determine
their concentration, and the absence of DNA was assessed by real-time RT-PCR
analysis. For cDNA synthesis, 500 ng of RNA was used as a template in a cDNA
synthesis reaction with Superscript III, using random primers [(NS)5] according
to the manufacturer’s instructions; no-reverse-transcriptase controls were in-
cluded in all analyses.
qRT-PCR. qRT-PCRs were carried out as previously described (30). Primers
were engineered to amplify the first 100 base pairs of the PA2934 open reading
frame. The rplU gene served as a control for all qRT-PCRs, as previous reports
have demonstrated that its transcription is independent of growth stage or
conditions across all P. aeruginosa strains assayed to date (30, 33). The data are
expressed as either relative input cDNA levels (in picograms) of cif transcript
compared to rplU transcript or total quantities of cDNA input for either the cif
or rplU gene. Input cDNA levels were determined by comparing cycle threshold
(CT) values obtained during the reactions to those obtained from a standard
DNA curve specific for either the cif or rplU gene. All qRT-PCRs were per-
formed using an ABI 7500 real-time PCR system (Applied Biosystems, Foster
City, CA).
Vesicle fractionation. Vesicles were purified from an overnight culture of P.
aeruginosa PA14 grown to stationary phase by using one of the following meth-
ods. The first method was modified from the procedure reported by Bauman and
Kuehn (1). Cells were removed by centrifugation, and supernatants were filtered
through a 0.45-m filter, followed by centrifugation at 39,000  g for 1 h at 4°C.
Pellets from centrifugation were resuspended in 50 mM HEPES buffer, pH 6.8,
and adjusted to 45% Optiprep in 10 mM HEPES containing 0.85% NaCl, pH 7.4
(wt/vol). Discontinuous Optiprep gradients were then layered over the vesicle
samples as follows: 0.8 ml 40% Optiprep, 0.8 ml 35% Optiprep, 1.6 ml 30%
Optiprep, and 0.8 ml 20% Optiprep in 10 mM HEPES–0.85% NaCl buffer.
Gradients were centrifuged at 100,000 g for 18 h at 4°C. Immediately following
centrifugation, 500-l fractions were collected from the gradients. Proteins in
each fraction were precipitated with 10% trichloroacetic acid (TCA) and visu-
alized by 12% SDS-PAGE and Coomassie blue staining.
Alternatively, we utilized a modified version of protocols published by Horst-
man and Kuehn (24) and Demuth et al. (12). Cells were removed by centrifu-
gation, and supernatants were filtered through a 0.45-m filter, followed by
concentrating the sample with an Amicon Ultra 15 30-kDa-cutoff membrane
filter by centrifugation at 4,000  g for 15 min. The filtered supernatant was
centrifuged at 45,000  g for 1 h; the pellet was resuspended in 4 ml of 20 mM
HEPES, pH 7.4, plus 500 mM NaCl, followed by a second centrifugation at
45,000  g for 1 h; and the pellet was again resuspended in 4 ml of 20 mM
HEPES, pH 7.4, plus 500 mM NaCl. Twenty microliters of 1.5% deoxycholate
and 200 l 72% TCA were added to 1 ml of the vesicle fraction and incubated
on ice for 10 min, followed by centrifugation at 16,000  g for 15 min at room
temperature. The pellet was washed twice with ice-cold 70% ethanol, and the
residual ethanol was evaporated by incubation at 65°C. The pellet was resus-
pended in 200 l of 1 SDS running buffer, and a 10-l sample was resolved by
SDS-PAGE and Western blotting, performed as reported previously (9). Similar
results were obtained using the two techniques.
Antibodies. Polyclonal rabbit anti-Cif antibodies were produced by Covance
Research Products (Denver, PA). Briefly, hexahistidine-tagged Cif was purified
as described above, using nickel-affinity chromatography, and diluted to a final
concentration of 1 mg/ml. The purified protein was then provided to Covance
Research Products for immunizations. Sera from day 51 bleeds were used at
1:1,000, using standard Western blotting techniques (9).
Antibody to the outer membrane protein OprF was produced against a par-
tially purified outer membrane fraction from P. aeruginosa. Specific cross-reac-
tivity to the OprF protein was determined in two ways. First, vesicles were
prepared by using the Optiprep gradient described above. The gradient fraction
shown previously to contain the suspected OprF cross-reacting band was TCA
precipitated, the proteins were resolved by SDS-PAGE, and a gel slice corre-
sponding to 37 kDa was excised and analyzed by mass spectroscopy at the
Dartmouth Proteomics Shared Resource. Five peptides matching OprF were
identified in this sample. Second, the loss of a cross-reacting band of the appro-
priate size (37 kDa) was observed for an oprF mutant strain. Nobuhiko No-
mura, Graduate School of Life and Environmental Sciences, University of
Tsukuba, generously provided the polyclonal antibody prior to publication.
RESULTS
Purification of Cif activity. Previous work by our group
demonstrated that exposing epithelial cells to P. aeruginosa
strain PA14 reduces apical membrane expression of CFTR
(48). We named the factor(s) responsible for this activity Cif
(48). Our published studies show that cell-free culture super-
natants also reduce apical membrane CFTR expression, thus
suggesting that Cif is secreted.
To determine the identity of Cif, we fractionated cell-free
supernatants from stationary-phase cultures, utilizing anion-
exchange chromatography and a step gradient of NaCl, and the
resulting fractions were assayed for the ability to decrease
apical membrane expression of CFTR in WT-CFBE cells. A
crude supernatant of P. aeruginosa PA14 reduced apical mem-
brane CFTR expression to 20% of the WT level in this
experiment (Fig. 1A). Upon fractionation of the supernatant,
we found that the two flowthrough fractions (F1 and F2) and
the fraction resulting from washing the column with 0 mM
NaCl (wash) lacked Cif activity. However, the Cif activity was
eluted from the column with 50 mM NaCl. Fraction E1 re-
sulted in5% of WT apical membrane CFTR expression (Fig.
1A, fraction E1). E2, a subsequent second fraction eluted with
2 M NaCl, also showed some Cif activity. The marked increase
in Cif activity observed in the E1 fraction compared to that in
the unfractionated supernatant was likely due to an increased
concentration of the factor in this fraction compared to that in
the crude supernatant, resulting in an increase in Cif activity.
SDS-PAGE analysis of the fractions demonstrated that
while fraction E1 was less complex than the crude supernatant,
it still contained approximately 25 proteins (Fig. 1B).
Identification of PA2934 as Cif. We next identified the pro-
teins in the Cif-containing fractions by utilizing MudPIT. Pep-
tide masses from the MudPIT analysis were compared to those
in the P. aeruginosa PA14 protein database (NCBI accession
no. nr 40070473), resulting in the identification of 20 proteins
from the E1 fraction that contained Cif activity (data not
shown).
Our previous work had suggested that Cif was secreted, and
size-exclusion chromatography demonstrated that Cif had a
mass of 	30 kDa (data not shown). Based on these previous
findings, candidate proteins were prioritized based on size,
the presence of secretory signals predicted by SMART
(http://smart.embl-heidelberg.de/), and predicted localization
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(PSORT [http://psort.nibb.ac.jp/]). The top three candidate
proteins, PA1914, PA2934, and PA4476, were selected for
further study.
Single-crossover mutations were created in the PA1914,
PA2934, and PA4476 genes, and the resulting mutants were
assayed for the ability to decrease apical membrane expression
of CFTR. Disrupting either the PA1914 or the PA4476 gene
did not result in any loss of Cif activity (data not shown).
Mutating the PA2934 gene with a single-crossover knockout
mutation resulted in a loss of Cif activity (not shown), as did
deletion of the PA2934 gene (Fig. 2A).
The PA2934 gene was cloned into the multicopy, arabinose-
inducible plasmid pMQ70 alone (not shown) or with a hexa-
histidine tag fused to the carboxy terminus of the protein,
resulting in plasmid pDPM73. Expression of the WT PA2934
protein from a multicopy plasmid (not shown) or of a His-
tagged variant of PA2934 (pDPM73/PA2934-His) (Fig. 2A)
was capable of complementing the mutation, thus demonstrat-
ing that a functional PA2934 protein is necessary for the pre-
viously reported Cif activity. The strain carrying the vector
control had no effect on apical CFTR expression (data not
shown). Furthermore, these data indicate that adding a His tag
to the C terminus of PA2934 has no apparent impact on the
function of the protein.
We next sought to determine if E. coli, which had previously
been shown to lack Cif activity, demonstrated Cif activity when
the PA2934-His protein was expressed in trans from a plasmid.
Indeed, although E. coli had no Cif activity, when the PA2934-
His protein was expressed in E. coli from an arabinose-induc-
ible promoter on a multicopy plasmid, we observed that the
resulting culture supernatants were capable of a small reduc-
tion in apical membrane expression of CFTR (Fig. 2B).
We also expressed Cif in P. aeruginosa PAO1, a strain pre-
viously shown to lack Cif activity (48), from plasmid pDPM73/
PA2934-His. This strain reduced apical membrane expression
20%, compared to the 40% reduction observed for strain
PA14. It is important to note that the basis for the lack of
detectable Cif expression in the PAO1 strain is not known; for
FIG. 1. Purification of Cif activity. (A) Apical membrane expression of CFTR following treatment of WT-MDCK cells with either LB medium
(vehicle control), unfractionated culture supernatant (Sup), or flowthrough (F1 and F2), wash, and elution (E1 and E2) fractions. Percent apical
membrane expression of CFTR was quantified as apical membrane expression of CFTR normalized to whole-cell lysate levels of CFTR relative
to that of the LB control. (B) SDS-PAGE and silver stain analysis of crude supernatant and fractions from anion-exchange chromatography.
Legend: SM, size markers; Sup, supernatant; F1 and F2, two flowthrough fractions; W, wash with 0 mM NaCl; E1, step elution with 50 mM NaCl;
E2, step elution with 2 M NaCl. Asterisks indicates fractions with Cif activity.
FIG. 2. PA2934 gene is necessary for Cif activity. (A) Apical membrane expression of CFTR in WT-MDCK cells exposed to LB medium or
supernatant from either the WT, the PA2934 mutant, or the PA2934 mutant containing plasmid pDPM73 (PA2934-His), which expresses the
His-tagged variant of the PA2934 protein. (B) Apical membrane expression of CFTR in WT-MDCK cells following incubation with LB medium
or supernatant from WT P. aeruginosa PA14, E. coli Top10 carrying the empty vector pMQ70, or E. coli Top10 expressing the PA2934-His protein
from plasmid pDPM73. For both panels, cultures were grown in LB medium for 18 h and the WT-MDCK cells were exposed to supernatants
for 10 min before assaying apical membrane CFTR levels. Percent apical membrane expression of CFTR was quantified as apical membrane
expression of CFTR normalized to whole-cell lysate levels of CFTR relative to that of the LB control. Asterisks indicate statistically significant
differences (P  0.05).
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example, this strain may be defective in secretion of Cif rather
than in its production.
It is noteworthy that Cif activity is somewhat variable, but
whether this is the result of Cif protein expression or interac-
tion with the host cell or is inherent in the assay itself is
unclear. Thus, this activity can vary from highly robust, as
demonstrated by the 90% reduction seen in Fig. 1A for the
unfractionated supernatant, to fairly low levels (20%). Fig-
ure 1A represents a single experiment from which the active
fraction identifying Cif was obtained. The data presented in
Fig. 2 and subsequent figures are the averages for a minimum
of four individual experiments, with three replicates per exper-
iment.
PA2934-His is a secreted protein. Assays for Cif activity
indicated that PA2934 is a secreted protein (48). To confirm
this prediction, we performed Western blot analysis of whole-
cell and supernatant fractions of P. aeruginosa carrying a plas-
mid which expressed PA2934-His (pDPM73) or the vector-
only control (pMQ70).
As shown in Fig. 3A, a cross-reacting band could be detected
in both the whole-cell and supernatant fractions of the
PA2934-His-expressing strain, but not the strain carrying the
vector, when probed with anti-His-tag antibody. To confirm
that the supernatant-localized PA2934-His was not a result of
cell lysis, we demonstrated that SadB, a known cytoplasmically
localized protein (9), was detected in the whole-cell fraction
but not the supernatant fraction of the same WT/pPA2934-
His-derived samples (Fig. 3B). These data indicate that the
PA2934-His protein found in the supernatant was not due to
cell lysis. Taken together with the predicted Sec secretion sig-
nal sequence at the N terminus of PA2934 and the activity
assays presented above, our data indicate that PA2934 is in-
deed secreted.
PA2934 is associated with extracellular vesicles. Several re-
cent reports have shown that P. aeruginosa and other microbes
package extracellular signaling molecules and toxins in outer
membrane-derived vesicles (OMVs) (12, 28, 36). Furthermore,
enterotoxigenic E. coli has been shown to deliver a toxin to a
eukaryotic host via its OMVs (28). Given that PA2934 is a
secreted protein and impacts eukaryotic cell function, we
tested the hypothesis that PA2934 might also be associated
with extracellular vesicles.
In studies using PA2934-His expressed from a plasmid (not
shown), we found PA2934-His in both the soluble fraction and
the pellet after centrifugation of culture supernatants at
40,000  g, conditions which are known to pellet OMVs (24).
We next investigated whether the WT PA2934 protein ex-
pressed in its native context is also associated with vesicles.
Membrane vesicles were prepared from the WT and the
PA2934 mutant, as reported previously (12, 24), and the
vesicle-containing fractions were probed with a polyclonal an-
tibody to the PA2934 protein. Consistent with the localization
of PA2934 protein to vesicles, a cross-reacting band migrating
at the expected molecular mass of 33 kDa was observed for
the vesicle fraction of the WT, but not that of the PA2934
mutant strain (Fig. 3C, top panel, arrow). Furthermore, the
same fractions were probed with a polyclonal antibody to the
outer membrane protein OprF, because vesicles have been
shown to accumulate outer membrane proteins (43). A cross-
reacting band of the expected size was detected in the vesicle
fraction of the WT but not in that of the oprF mutant (Fig. 3C,
bottom panel). These data indicate that PA2934 is likely asso-
ciated with membrane vesicles.
Purified PA2934-His decreases apical membrane expression
of CFTR. To demonstrate that PA2934 is both necessary and
sufficient for Cif activity, we purified the PA2934-His protein
from culture supernatants. The PA2934-His protein could be
detected in crude cell-free supernatants (Fig. 4A) of an arabi-
nose-induced E. coli strain expressing this protein from an
arabinose-inducible promoter (pDPM73). Using the His-affin-
ity resin, the PA2934-His protein was purified to apparent
homogeneity from culture supernatants (Fig. 4A). The bands
observed both in the crude supernatants and in fractionated
samples correspond with the predicted size of Cif, at 33 kDa.
When the purified PA2934-His protein was applied to WT-
MDCK cells, it was capable of a time-dependent reduction of
apical membrane expression of CFTR (Fig. 4B). By 60 min
after treatment with PA2934-His, the apical membrane expres-
sion of CFTR was reduced 	60%, and it was reduced 	70%
at 90 min. Similar results were obtained when PA2934-His was
applied to the apical surfaces of WT-CFBE cells (Fig. 4C),
indicating that the effects of PA2934-His on CFTR are not cell
line dependent. These data demonstrate that PA2934 is both
necessary and sufficient for the previously described Cif activ-
FIG. 3. PA2934-His is secreted. (A) Western blot analysis of the whole-cell pellet (WC) and cell-free supernatant (S) of P. aeruginosa PA14
carrying either the PA2934-His-expressing plasmid pDPM73 (pPA2934-His) or the empty vector pMQ70. Protein (2.5 g) from each sample was
resolved by SDS-PAGE, transferred to a membrane, and probed using a monoclonal antipolyhistidine antibody. (B) Western blot analysis of
identical fractions to those from panel A from the P. aeruginosa strain carrying plasmid pDPM73 (pPA2934-His). Samples were probed with
polyclonal anti-SadB antibodies. The arrow indicates SadB, and the lower band is a nonspecific cross-reacting band reported previously (9).
(C) Vesicles were purified from the WT, PA2934, and oprF::Tn5-B22 (oprF) strains as described in Materials and Methods and used in Western
blot experiments. Samples were probed with either polyclonal anti-PA2934 (left) or polyclonal anti-OprF (right) antibodies. The arrow indicates
the PA2934-specific band.
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ity. These findings have prompted us to rename the PA2934
gene and the resulting protein product cif and Cif, respectively,
for CFTR inhibitory factor.
It should be noted that while the experiments presented here
show percentages of apical CFTR normalized to whole-cell
levels of CFTR, in previous studies we have normalized apical
CFTR to ezrin and total cellular protein levels (48), clearly
demonstrating that Cif activity decreases apical CFTR expres-
sion.
Cif inhibits CFTR-mediated chloride secretion. Our previ-
ous report demonstrated that the decrease in apical membrane
expression of CFTR following treatment with Cif-containing
culture supernatants was accompanied by a decrease in CFTR-
mediated chloride secretion (48). In order to demonstrate that
purified Cif was sufficient for both the decreased apical mem-
brane expression of CFTR and the decrease in CFTR-medi-
ated chloride secretion, we performed Ussing chamber exper-
iments using the purified Cif-His protein.
Purified Cif-His protein added to the apical face of these
cells inhibited forskolin-stimulated, CFTR-mediated Cl ion
secretion by almost 30 A/cm2, whereas buffer alone had no
significant effect on forskolin-stimulated CFTR Cl current
(Fig. 4D). As a control, the addition of the specific CFTR
inhibitor CFTRinh-172 (32) to WT-CFBE cells reduced fors-
kolin-stimulated, CFTR-mediated Cl ion secretion by almost
50 A/cm2 (not shown). Thus, recombinant Cif-His reduced
CFTR Cl currents by 60% and apical plasma CFTR Cl
ion channel expression by approximately the same amount
(60%) (Fig. 4B).
Cif demonstrates epoxide hydrolase activity. Bioinformatic
analysis suggests that the cif gene may belong to a three-gene
operon including morB, encoding a predicted morphinone re-
ductase, and the PA2933 gene, which is predicted to encode an
MFS family transporter. The Cif protein is predicted to contain
an 
/ hydrolase fold. Besides the secretion signal, no other
known domain was detected in the Cif protein. The 
/ hy-
drolase superfamily is comprised of several subfamilies of pro-
teins, including acyltransferases, lipases, lysophospholipases,
and epoxide hydrolases (23). Further examination of the pro-
tein sequence suggested that Cif contains domains consistent
with those of epoxide hydrolases, a diverse family of proteins
associated with the degradation of xenobiotic compounds and
involved in mammalian cell signaling.
To assess whether Cif acts as an epoxide hydrolase, we
assessed its ability to degrade the synthetic epoxide hydrolase
substrate (S)-NEPC. The assay used measures the production
FIG. 4. PA2934 is sufficient for Cif activity. (A) Coomassie blue-stained SDS-PAGE gel of supernatant from E. coli Top10 cells carrying
pDPM73 (PA2934-His) and of purified PA2934-His. Ten micrograms of protein from each sample was resolved via SDS-PAGE and stained using
Coomassie brilliant blue. (B) Purified PA2934-His decreases apical membrane expression of CFTR in a time-dependent manner. Fifty micrograms
of purified PA2934-His was added to the apical membranes of WT-MDCK cells and incubated for either 30, 60, or 90 min, followed by Western
blot analysis to determine apical membrane expression of CFTR. (C) Apical membrane expression of CFTR in WT-CFBE cells was determined
at 60 min as described for panel B. (D) Ussing chamber experiment to assay the effect of purified Cif-His protein or the Cif(H269A)-His mutant
protein on CFTR-mediated Cl secretion in WT-CFBE cells. The forskolin-stimulated Isc values were measured as described in Materials and
Methods. Isc data are expressed as changes in forskolin-stimulated Isc. Asterisks indicate statistically significant differences from the buffer (P 
0.05).
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of the product p-nitrophenol, which is yellow and absorbs max-
imally at 405 nm. As shown in Fig. 5A, purified Cif was capable
of degrading this compound in a protein concentration-depen-
dent manner during the 60-min incubation period of the assay.
Control experiments demonstrated that the Cif protein does
not absorb at 405 nm, and thus the increase in absorbance was
due to degradation of the substrate.
Cif hydrolase activity requires the invariant histidine resi-
due. Members of the 
/ hydrolase family, including typical
epoxide hydrolases, are characterized by the presence of a
catalytic triad consisting of a nucleophilic residue, an acidic
residue, and a highly conserved histidine, located within three
separate loops of the protein (23). Examination of the amino
acid sequence of Cif identified these residues, including the
invariant histidine residue. We created a mutant variant of Cif
in the purification vector, wherein the histidine residue at po-
sition 269 was replaced with an alanine residue. Western blot
analysis of E. coli expressing either Cif-His or the Cif(H269A)-
His variant demonstrated that the H269A variant was stably
expressed (Fig. 5B).
The Cif(H269A)-His protein was purified to apparent ho-
mogeneity by the same method described for the WT Cif-His
protein and then assayed for epoxide hydrolase activity as
described above. The H269A mutation significantly reduced
the epoxide hydrolase activity of this variant compared to that
of the WT protein, resulting in activity at or near the levels
seen for the buffer control (Fig. 5C).
Loss of epoxide hydrolase activity correlates with a loss of
Cif activity. To correlate epoxide hydrolase activity with the
previously described Cif activity, we tested the ability of the
purified H269A variant of Cif to decrease apical membrane
expression of CFTR. The WT Cif-His protein significantly
decreased the apical membrane expression of CFTR, but the
Cif(H269A)-His mutant protein had no effect on the apical
membrane expression of CFTR in WT-MDCK cells (Fig. 5D).
Similarly, the Cif(H269A)-His mutant protein had little or no
effect on CFTR-mediated Cl secretion in WT-CFBE cells
(Fig. 4D). These data, along with the observation that the
H269A mutant lacks epoxide hydrolase activity, suggest that
epoxide hydrolase activity is linked to Cif activity.
cif gene expression is higher in nonmucoid clinical isolates
than in mucoid clinical isolates. To better understand the
potential clinical relevance of Cif activity, we sought to char-
acterize cif gene expression in P. aeruginosa clinical isolates,
specifically those isolates that originated from CF patients. To
do this, we first divided the clinical isolates from CF patients
FIG. 5. Biochemical characterization of Cif. (A) Cif degrades the epoxide hydrolase substrate (S)-NEPC in a concentration-dependent manner.
Various amounts of purified Cif-His, as indicated, were incubated with 100 M of (S)-NEPC in 20 mM Tris, pH 8.5, and 500 mM NaCl for 20
min, and substrate degradation was determined by an increase in absorbance (OD405). Results are reported as net enzyme-mediated substrate
degradation. Spontaneous degradation, as measured by the absorbance of the substrate in the assay buffer lacking enzyme, was subtracted from
the absorbance under experimental conditions. (B) Supernatants from E. coli cultures carrying either the empty vector (pMQ70) or a plasmid
expressing Cif-His (pDPM73) or the Cif(H269A)-His mutant (pDPM77) were harvested via centrifugation, filtered, resolved by SDS-PAGE, and
probed using a monoclonal antihexahistidine antibody. (C) The Cif(H269A)-His mutant protein is incapable of degrading (S)-NEPC. One hundred
micrograms of either the purified Cif-His protein or the Cif(H269A)-His mutant protein was assayed for the ability to degrade (S)-NEPC, as
described above. (D) Fifty micrograms of either purified WT Cif or the purified Cif(H269A)-His mutant protein was added to the apical
membranes of WT-MDCK monolayers. Apical membrane expression of CFTR was assayed via Western blotting and normalized to whole-cell
lysate CFTR.
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into either mucoid or nonmucoid strains, based on their phe-
notypes on solid LB medium (data not shown). Nonmucoid
strains are typically associated with early infection of the CF
lung, while mucoid strains are associated with chronic lung
infections (13, 14, 35).
To quantitatively assess cif gene expression, strains were
grown in LB medium to an OD600 of 2.5, the total cellular
RNA was harvested, and qRT-PCR was performed. Interest-
ingly, we found that expression of the cif gene was significantly
higher in all five nonmucoid clinical isolates than in P. aerugi-
nosa PA14 (set arbitrarily at 1 in this experiment) and the
mucoid P. aeruginosa strains (Fig. 6A).
The cif gene is transcribed in P. aeruginosa cells growing in
the CF lung. To investigate whether cif might play a role in the
context of the CF lung, we tested whether the population of P.
aeruginosa cells residing in sputum within the CF lung ex-
pressed this gene. Total RNAs were purified from the sputa of
two CF patients, cDNAs were synthesized, and the expression
of the cif gene was assessed by qRT-PCR. As shown in Fig. 6B,
the cif gene transcript was indeed detectable in the sputum
samples of both patients tested, as was the constitutively ex-
pressed rplU gene, suggesting that cif is transcribed in the CF
airway. It should be noted that expression levels of the rplU and
cif genes for both of the patients tested were several orders of
magnitude higher than those for the no-reverse-transcriptase
controls. Furthermore, the transcript level for each gene and
the relative expression pattern seen for these two patients, with
rplU expression exceeding cif expression, were similar to those
observed for the mucoid clinical isolates described above.
DISCUSSION
We previously demonstrated that P. aeruginosa secretes a
factor capable of decreasing the apical membrane expression
of both WT and F508 CFTR (48). Here we continued this
work, first purifying and identifying the factor as the product of
the PA2934 gene and then demonstrating both the necessity
and sufficiency of this gene (cif) and its product (Cif) for the
previously described activity. We show that Cif both decreases
apical CFTR expression and reduces CFTR-mediated Cl ion
secretion, indicating that Cif activity has a functional impact on
the biology of airway cells relevant to CF.
Our data show that Cif is a secreted protein and that super-
natants of P. aeruginosa are sufficient to observe Cif activity.
Therefore, direct contact of the bacterium with the airway cells
is not necessary for Cif to exert its effects on these cells.
Furthermore, our data show that Cif is associated with mem-
brane vesicles, indicating that fusion of the diffusible vesicles
with epithelial cells may be one mechanism by which Cif enters
the cytosol of eukaryotic cells (24). Recent data support the
idea that biofilms of P. aeruginosa in the CF lung may form in
the mucus above the airway cells rather than directly on the
airway cells (51). However, given that Cif is secreted and likely
diffusible in the context of the CF lung and that purified Cif
protein in the absence of bacteria is sufficient to decrease
apical membrane CFTR expression, this toxin would still be
capable of impacting airway cell biology in CF even if ex-
pressed from bacteria in the mucus.
It is widely accepted that bacteria are capable of altering
trafficking in eukaryotic cells. For example, both Mycobacte-
rium tuberculosis and Legionella pneumophila rely on their abil-
ity to arrest phagosomal maturation during infection of mac-
rophages (4, 44, 49). While the alteration of trafficking is
relatively commonplace among intracellular pathogens, it is
not typically associated with extracellular pathogens such as P.
aeruginosa. Therefore, Cif-mediated alteration of CFTR traf-
ficking may represent a novel mechanism of altering the cell
biology of the host by an extracellular pathogen. We speculate
that the alteration of protein localization following secretion of
Cif creates an environment conducive for P. aeruginosa colo-
nization. That is, in the context of CF, Cif may further reduce
any residual Cl ion secretion and airway surface liquid vol-
ume and thereby further reduce mucociliary clearance, allow-
ing establishment of the P. aeruginosa infection and, eventu-
ally, biofilm formation.
We demonstrated that Cif can catalyze the degradation of a
FIG. 6. Expression of cif in clinical isolates and in CF sputum. (A) qRT-PCR analysis of cif gene expression in WT P. aeruginosa PA14 and in
mucoid and nonmucoid P. aeruginosa clinical strains isolated from CF sputa. Expression levels were quantified as picograms of input cDNA and
normalized to rplU expression. Values are relative to the cif gene transcript level observed for P. aeruginosa PA14 (arbitrarily set to 1).
(B) qRT-PCR analysis of cif and rplU expression levels in RNAs purified from the sputa of CF patients. Expression levels were quantified as
picograms of input cDNA based on a standard DNA curve.
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model substrate of epoxide hydrolases, (S)-NEPC, which was
demonstrated previously to be a substrate of a murine epoxide
hydrolase (15). Both the primary amino acid sequence of Cif
and its predicted secondary structure place this protein within
the broad family of 
/ hydrolase enzymes. Interestingly, pro-
teins in this family share a conserved 
/ fold motif as well as
a conserved catalytic triad. Consistent with Cif’s identification
as a member of the 
/ hydrolase family, we have shown that
mutating the invariant histidine residue predicted to comprise
the conserved catalytic triad, i.e., His269, to Ala results in a
loss of epoxide hydrolase activity.
Many of the members of the 
/ hydrolase family are con-
sidered promiscuous based on their ability to degrade a num-
ber of different ester-based bonds with various affinities (23).
Thus, while Cif is capable of hydrolyzing a model epoxide
substrate in vitro, the decreased apical membrane expression
of CFTR mediated by Cif in vivo may result from this enzyme
acting on a very different substrate. Identifying the authentic
substrate for this protein is the subject of ongoing studies.
The expression and secretion of epoxide hydrolases by
pseudomonads have been reported previously. Work by Jacobs
et al. identified a protein in culture supernatants of a soil
pseudomonad capable of degrading the epoxide epichlorohy-
drin (26). Interestingly, a partial sequence of 50 amino acids
of this epichlorohydrin hydrolase showed 40% identity and
62% similarity to Cif (PA2934) of P. aeruginosa. It was the
similarity of PA2934 to this reported epichlorohydrin hydro-
lase that prompted us to test Cif for this activity.
The demonstration that the cif transcript is detectable within
CF sputum suggests that this gene, and perhaps its protein
product, may be expressed in the CF airway and thus may
contribute to the pathogenesis of P. aeruginosa in this context.
It should be noted that common CF airway pathogens, includ-
ing Staphylococcus aureus, Stenotrophomonas maltophilia, and
Haemophilus influenzae, apparently lack the cif gene, based on
BLAST analysis. Interestingly, a potential homolog sharing
38% amino acid sequence identity with Cif was observed in
Burkholderia cepacia. Therefore, it is possible that the cif tran-
script detected might reflect combined expression of this gene
from P. aeruginosa and B. cepacia. Furthermore, the data dem-
onstrating that cif gene expression is relatively high in nonmu-
coid isolates, which are associated with early colonization of
the CF lung, and relatively low in mucoid isolates, which are
associated with the long-term chronic colonization of the CF
lung, suggest that cif expression may be temporal in nature (13,
14, 35). Specifically, cif gene expression may be important early
in the colonization of the CF lung but may play little or no role
in later chronic infection processes.
The data above prompted us to propose a two-stage model
of CF lung infection in which Cif plays a key role in the initial
stage of infection, perhaps by further reducing CFTR expres-
sion in CF patients and thus facilitating subsequent biofilm
formation by P. aeruginosa. In this model, P. aeruginosa enters
the lung and may be able to gain an initial foothold due to the
decreased expression of CFTR in a CF patient and the asso-
ciated decrease in mucociliary clearance and other innate re-
sistance pathways. P. aeruginosa strains expressing Cif may
have a selective advantage in continued persistence in the lung
because these organisms can further decrease the already de-
pleted levels of apical membrane CFTR, thus resulting in the
inability of the lung to clear this microbe. As lung function
decreases, the bacterial infection progresses, leading eventu-
ally to biofilm formation and the mucoid phenotype, wherein
Cif function is no longer required and therefore there may be
a selective advantage in down regulating its expression. We
believe that this model could account for why P. aeruginosa is
particularly suited to infect the CF lung.
Much of the focus in the area of CF therapeutics has cen-
tered on discovering compounds capable of increasing apical
membrane expression of the F508-CFTR protein. The ratio-
nale underlying such a strategy is that increased CFTR activity
and increased Cl ion secretion would result in decreased
mucous viscosity, increased mucociliary clearance, and resolu-
tion of infections and symptoms. The work presented here and
our earlier work suggest that in the presence of P. aeruginosa,
as is the case for the majority of CF patients, this treatment
course might be ineffectual, as any increase in F508-CFTR
protein would be reversed due to the activity of Cif. Thus, any
attempt to increase apical membrane expression of F508-
CFTR may need to be coupled to either an antipseudomonas
regimen of antibiotics or compounds specifically targeted to
Cif function.
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